SCHEDULE APPOINTMENT: CALL 800.999.1249 OR SCHEDULE ONLINE
>18 YEARS OLD. ASTHMA STUDY
If you are interested in participating and believe you meet the requirements, please contact our research staff to learn more at 502.368.0732.
Explore More About These Research Trials
An easy way to track when your study milestones, treatments, or updates are expected.
> 18 YEARS OLD. {ASTHMA STUDY}
- The investigational medicinal product will be Dupilumab, or matching placebo supplied in a prefilled syringe to deliver 300 mg in a 2mL injection. Loading dose of 600mg at first dose, then 300mg given Q 2 weeks.
- The purpose of the study is to assess the effect of Dupilumab on preventing or slowing the rate of lung function decline, (Rate of change to week 52 on post-BD FEV1 slope).
- Duration: Screening and run-in period up to 4 weeks, followed by a 3-year double blind treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.
Key Inclusion Criteria:
- Participant will need to have been diagnosed with asthma (according to GINA 2020) for > 12 months and treated with medium to high dose ICS in combination with a second controller (e.g., LABA, LTRA) for at least 3 months with stable dose > 1month prior to visit 1.
- History of > 1 exacerbation(s) in the previous year before V1.
Key Exclusion:
- History or clinical evidence of COPD including Asthma-COPD Overlap. Known or suspected immunodeficiency. Treatment with oral corticosteroids (OCS) for more than 2 weeks before V1.
- Current smoker (cigarette or e-cigarette) or cessation of smoking within 6 months to visit 1 OR previous smoker with > 10 pack year smoking history.
Explore More About These Research Trials
An easy way to track when your study milestones, treatments, or updates are expected.
Interested in hearing more about these Research Trials?
Please contact one of our staff at 502.368.0732 or fill out the form below: